세계의 암 분자진단 시장 : 암 유형별, 제품 유형별, 장소별 시장 예측 - 경영진 컨설턴트 가이드 (2025-2029년) - 인공지능(AI)의 영향

Molecular Diagnostics for Cancer. Markets Forecasts by Cancer Type, Product and Place with Executive and Consultant Guides and Impact of Artificial Intelligence. 2025 to 2029

US $ 6,995 ￦ 9,757,000

PDF (Single User License)

PDF 보고서를 1명(One device)만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,495 ￦ 14,639,000

PDF (Five User License)

PDF 보고서를 동일 사업장의 5명(Five devices)까지 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 13,995 ￦ 19,521,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄는 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

암 분자진단은 다시 성장 궤도에 올라섰습니다. 그리고 모든 부문에서 성장이 가속화되고 있습니다. 본 보고서에서는 암 동반진단이라는 새로운 시장 부문을 특별하게 다루고 있으며, 140개 이상의 기업 프로파일이 수록되어 있습니다. 다양한 트렌드가 시장의 성장과 기업의 가치를 높이고 있습니다.

그 동향은 다음과 같습니다.

• 맞춤형 의료
• 약물유전체학
• 액체생검
• 최소잔존병변 검사
• 큰 시장을 가진 새로운 경제권의 출현
• 새로운 지능형 진단 검사로 대체되고 있는 의사의 진단을 대체하고 있습니다.

특히 동반진단 분야의 흥미로운 기술 개발은 단일 검사기관이 전 세계 환자를 대상으로 하는 역동적으로 성장하고 진화하는 세계 시장의 도래를 예고하고 있습니다.

이 보고서에는 사용자 정의, 특정 부문에 대한 브레이크 아웃, 지원 및 지원이 무료로 포함되어 있습니다.

본 보고서에는 18개 국가와 4개 지역에 대한 상세한 분석이 포함되어 있습니다. 보고서 구매자는 전 세계 모든 국가에 대한 상세한 분석 결과를 얻을 수 있습니다.

세계의 암 분자진단제 시장에 대해 조사했으며, 시장 개요와 함께 암 유형별, 제품 유형별, 지역별, 지역별 동향, 시장 진출기업 프로파일 등의 정보를 전해드립니다.

목차

제1장 시장 가이드

제2장 서론과 시장의 정의

• 분자진단이란 무엇인가
• 진단 혁명
• 시장 정의
• 조사 방법
• 시점 : 헬스케어와 IVD 업계

제3장 시장 개요

• 시장 부문
• 업계 구조

제4장 시장 동향

• 성장 촉진요인
• 성장 억제요인
• 계측, 자동화 및 진단 동향

제5장 분자진단의 최근 동향

제6장 주요 기업 개요

• 10x Genomics, Inc.
• Abbott Laboratories
• AccuraGen Inc.
• Acuamark Diagnostics
• Adaptive Biotechnologies
• Admera Health, LLC
• Aethlon Medical
• Agilent
• Amoy Diagnostics Co., Ltd.
• Anchor Dx
• ANGLE plc
• ARUP Laboratories
• AVIVA Systems Biology
• Baylor Miraca Genetics Laboratories
• Beckman Coulter Diagnostics(Danaher)
• Becton, Dickinson and Company
• BGI Genomics Co. Ltd
• BillionToOne
• Bioarray Genetics
• Biocartis
• Biocept, Inc.
• Biodesix Inc.
• BioFluidica
• BioGenex
• BioIVT
• Biolidics Ltd
• bioMerieux Diagnostics
• Bioneer Corporation
• Bio-Rad Laboratories, Inc
• Bio-Reference Laboratories
• Bio-Techne
• Bioview
• Bristol-Myers Squibb
• Burning Rock
• C2i Genomics
• Cardiff Oncology
• Caris Molecular Diagnostics
• Castle Biosciences, Inc.
• Celemics
• CellCarta
• CellMax Life
• Cepheid(Danaher)
• Charles River Laboratories
• Circulogene
• Cizzle Biotech
• Clearbridge Biomedics
• Clinical Genomics
• Cytolumina Technologies Corp.
• Datar Cancer Genetics Limited
• Diagnologix LLC
• Diasorin S.p.A.
• Dxcover
• Element Biosciences
• Enzo Biochem
• Epic Sciences
• Epigenomics AG
• Erythra
• Eurofins Scientific
• Exact Sciences
• Fabric Genomics
• Fluxion Biosciences(Cell Microsystems)
• Freenome
• FUJIFILM Wako Diagnostics
• Fujirebio
• Fulgent Genetics
• Fyr Diagnostics
• GeneDx Holdings
• GeneFirst Ltd.
• Genetron Holdings
• GenomOncology
• GILUPI Nanomedizin
• Guardant Health
• HansaBiomed
• HTG Molecular Diagnostics
• iCellate
• ICON PLC
• Illumina
• Incell Dx
• Inivata
• INOVIQ
• Invitae Corporation
• Invivogen
• Invivoscribe
• J&J Innovative Medicine
• Lucence Health
• Lunglife AI Inc
• MDNA Life SCIENCES, Inc.
• MDx Health
• Menarini Silicon Biosystems
• Mesa Laboratories, Inc.
• Metabiomics Corp
• Millipore Sigma
• Miltenyi Biotec
• miR Scientific
• Myriad Genetics
• Nanostring
• NantHealth, Inc.
• Natera
• NeoGenomics
• NGeneBio
• Novogene
• Oncimmune
• Oncocyte
• OncoDNA
• Oncohost
• OraLiva
• Oxford Nanopore Technologies
• PamGene
• Panagene
• Personalis
• Perthera
• PGDx(Labcorp)
• Precipio
• PrecisionMed
• Predicine
• Predictive Oncology
• Prenetics
• Promega
• Qiagen
• QuidelOrtho
• Rarecells SAS
• RareCyte
• Revvity
• Roche Diagnostics
• Screencell
• Sherlock Biosciences
• Siemens Healthineers
• simfo GmbH
• Singlera Genomics Inc.
• Singular Genomics
• Singulomics
• SkylineDx
• Standard BioTools
• Stilla Technologies
• Sysmex Inostics
• Tempus Labs, Inc.
• Thermo Fisher Scientific
• Todos Medical
• Ultima Genomics
• Variantyx
• Vela Diagnostics
• Veracyte
• VolitionRX
• Vortex Biosciences
• Zhejiang Orient Gene Biotech

제7장 세계의 암 분자진단시장

• 암 분자진단 - 국가별 세계 시장 개요
• 암 유형별 세계 시장 - 개요
• 제품 유형별 세계 시장 - 개요
• 장소별 세계 시장 - 개요

제8장 암 유형별 세계 시장

• 유방암
• 대장암
• 자궁경부암
• 폐암
• 전립선
• 흑색종 암
• 혈액암
• 동반진단약 개발
• 기타

제9장 제품 유형별 세계 시장

• 기기
• 시약
• 소프트웨어 및 서비스

제10장 지역별 세계 시장

• 임상실험실
• 제약
• 연구

제11장 암치료와 임상시험

• FDA 승인(연도별, 신청별)
• 임상시험 개시
• 암치료 보급률

제12장 부록

LSH

영문 목차

영문목차

OVERVIEW:

Cancer Molecular Diagnostics is back on the growth path. And growth is accelerating in every segment. We include a special segment Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. Over 140 companies are profiled. A range of dynamic trends are pushing market growth and company valuations.

Trends like:

• personalized medicine
• pharmacogenomics
• liquid biopsy
• minimal residual disease testing
• emergence of new economies with large markets
• physician diagnostics being displaced by new intelligent diagnostic tests

Exciting technical developments especially in companion diagnostics, hold the promise of a dynamic, growing and evolving world market where single laboratories serve a global patient base.

In addition customization work, breakouts for particular segments, assistance and support is included free of charge with every report.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

Table of Contents

1. Market Guides

• 1.1. Cancer MDx - Strategic Situation Analysis
• 1.2. Guide for Executives, Marketing, and Business Development Staff
• 1.3. Guide for Management Consultants and Investment Advisors
• 1.4. Impact of Artificial Intelligence on Cancer MDx

2. Introduction and Market Definition

• 2.1. What are Molecular Diagnostics?
• 2.2. The Diagnostics Revolution
• 2.3. Market Definition
  • 2.3.1. Revenue Market Size
• 2.4. Methodology
  • 2.4.1. Methodology
  • 2.4.2. Sources
  • 2.4.3. Authors
• 2.5. Perspective: Healthcare and the IVD Industry
  • 2.5.1. Global Healthcare Spending
  • 2.5.2. Spending on Diagnostics
  • 2.5.3. Important Role of Insurance for Diagnostics

3. Market Overview

• 3.1. Market Segments
  • 3.1.1. Traditional Market Segmentation
  • 3.1.2. Laboratory Focus and Segmentation
• 3.2. Industry Structure
  • 3.2.1. Hospital Testing Share
  • 3.2.2. Economies of Scale
  • 3.2.3. Physician Office Lab's
  • 3.2.4. Physician's and POCT

4. Market Trends

• 4.1. Factors Driving Growth
  • 4.1.1. New Diagnostics Create New Markets
  • 4.1.2. New Roles for Diagnostics
  • 4.1.3. Aging Effect
  • 4.1.4. Expanding the Pharmaceutical Toolbox
  • 4.1.5. Regulatory Retreat
• 4.2. Factors Limiting Growth
  • 4.2.1. Falling Prices
  • 4.2.2. Lower Costs
  • 4.2.3. Wellness has a Downside
• 4.3. Instrumentation, Automation and Diagnostic Trends
  • 4.3.1. Traditional Automation and Centralization
  • 4.3.2. The New Automation, Decentralization and Point Of Care
  • 4.3.3. Instruments Key to Market Share
  • 4.3.4. Bioinformatics Plays a Role
  • 4.3.5. PCR Takes Command
  • 4.3.6. Next Generation Sequencing Fuels a Revolution
  • 4.3.7. NGS Impact on Pricing
  • 4.3.8. Whole Genome Sequencing, A Brave New World
  • 4.3.9. Companion Diagnostics Blurs Diagnosis and Treatment
  • 4.3.10. Shifting Role of Diagnostics
  • 4.3.11. Multiplexing and Foundation One
  • 4.3.12. Pharmacogenomics Technology
  • 4.3.13. Gene Editing and Gene Therapy

5. Molecular Diagnostics Recent Developments

• 5.1. Recent Developments - Importance and How to Use This Section
  • 5.1.1. Importance of These Developments
  • 5.1.2. How to Use This Section
• 5.2. Guardant Health Guardant360 Tissue
• 5.3. AccuStem Sciences & EmeritusDx partner for Lung Cancer Screening
• 5.4. LetsGetChecked LaunchesHereditary Cancer Test
• 5.5. Guardant Health's Colorectal Test New Status
• 5.6. Tempus xT CDx
• 5.7. OneCell Diagnostics Raises $16M
• 5.8. A. Menarini to use Nucleix Bladder Cancer Test
• 5.9. Foundation Medicine, Repare Therapeutics to Develop CDx
• 5.10. NHS Declines to Accelerate Grail Galleri Implementation
• 5.11. GeneDx Sees Growing Demand for Testing
• 5.12. Thermo Fisher and Bayer to Develop CDx for Cancer Therapies
• 5.13. ClearNote Health Expands Into Immunotherapy Monitoring
• 5.14. Foundation Medicine to Collaborate on CDx for Lung Cancer
• 5.15. Qiagen and Myriad Genetics Partner to Develop Cancer CDx
• 5.16. Lung Cancer Data Heralds Shift for Hummingbird Dx
• 5.17. PamGene Awarded Euro-7.5M for Immunotherapy Test
• 5.18. Grail Cancer Test Faces New Clinical Questions
• 5.19. Freenome Acquires Cancer Dx Firm Oncimmune
• 5.20. Quest Diagnostics to Acquire Liquid Biopsy Firm Haystack Oncology
• 5.21. Ultima Genomics, Genome Insight Partner on WGS for Cancer Patients
• 5.22. Digital Pathology Meets Cancer Sequencing
• 5.23. Exact Sciences Preps Expanded Oncology Portfolio
• 5.24. Qiagen Details Oncology Plans for Digital PCR Platform
• 5.25. Sema4 Exiting Reproductive Health Screening
• 5.26. Thermo Fisher Introduces Cancer Profiling Assay
• 5.27. Genomic Test IDs Cysts Likely to Progress to Cancer
• 5.28. Naveris to Commercialize Virus-Related Cancer Tests
• 5.29. Larger Liquid Biopsy Panels Loom
• 5.30. Halo Diagnostics to Offer Genomic Profiling Tests
• 5.31. BillionToOne Raises $125M
• 5.32. Local Cancer Genomic Profiling Options Grow
• 5.33. German MDx Firm Mainz Biomed Raises $10M in IPO
• 5.34. Guardant Health Q3 Revenues Up 27 Percent
• 5.35. BforCure Raises $2.3M to Adapt Rapid PCR Platform for Cancer Detection
• 5.36. Nucleix to Invest in Early-Stage Lung Cancer Dx
• 5.37. Labcorp, GeneCentric Partnering on Development of RNA-Based Cancer Diagnostics
• 5.38. Grail Gets Approval for Galleri Multicancer Test
• 5.39. Finnish Firms to Form Point-of-Care Testing Firm
• 5.40. Datar Cancer Genetics Expands to Dx and Screening
• 5.41. HTG Molecular Diagnostics: HTG Transcriptome Panel
• 5.42. PacBio's Omniome Acquisition Shortens Path to Clinical
• 5.43. Invitae to Acquire Genosity for $200M
• 5.44. Bio-Techne Obtains CE Mark for Exosomal Liquid Biopsy Prostate Test
• 5.45. Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience
• 5.46. Natera Revenues Grow 35 Percent
• 5.47. AnchorDx Closes $40M Financing Round
• 5.48. Exact Sciences Strategy for End-to-End Cancer Testing
• 5.49. Genomics England: Whole Genome Sequencing for Cancer Patients to Launch

6. Profiles of Key MDx Companies

• 6.1. 10x Genomics, Inc.
• 6.2. Abbott Laboratories
• 6.3. AccuraGen Inc.
• 6.4. Acuamark Diagnostics
• 6.5. Adaptive Biotechnologies
• 6.6. Admera Health, LLC
• 6.7. Aethlon Medical
• 6.8. Agilent
• 6.9. Amoy Diagnostics Co., Ltd.
• 6.10. Anchor Dx
• 6.11. ANGLE plc
• 6.12. ARUP Laboratories
• 6.13. AVIVA Systems Biology
• 6.14. Baylor Miraca Genetics Laboratories
• 6.15. Beckman Coulter Diagnostics (Danaher)
• 6.16. Becton, Dickinson and Company
• 6.17. BGI Genomics Co. Ltd
• 6.18. BillionToOne
• 6.19. Bioarray Genetics
• 6.20. Biocartis
• 6.21. Biocept, Inc.
• 6.22. Biodesix Inc.
• 6.23. BioFluidica
• 6.24. BioGenex
• 6.25. BioIVT
• 6.26. Biolidics Ltd
• 6.27. bioMerieux Diagnostics
• 6.28. Bioneer Corporation
• 6.29. Bio-Rad Laboratories, Inc
• 6.30. Bio-Reference Laboratories
• 6.31. Bio-Techne
• 6.32. Bioview
• 6.33. Bristol-Myers Squibb
• 6.34. Burning Rock
• 6.35. C2i Genomics
• 6.36. Cardiff Oncology
• 6.37. Caris Molecular Diagnostics
• 6.38. Castle Biosciences, Inc.
• 6.39. Celemics
• 6.40. CellCarta
• 6.41. CellMax Life
• 6.42. Cepheid (Danaher)
• 6.43. Charles River Laboratories
• 6.44. Circulogene
• 6.45. Cizzle Biotech
• 6.46. Clearbridge Biomedics
• 6.47. Clinical Genomics
• 6.48. Cytolumina Technologies Corp.
• 6.49. Datar Cancer Genetics Limited
• 6.50. Diagnologix LLC
• 6.51. Diasorin S.p.A.
• 6.52. Dxcover
• 6.53. Element Biosciences
• 6.54. Enzo Biochem
• 6.55. Epic Sciences
• 6.56. Epigenomics AG
• 6.57. Erythra
• 6.58. Eurofins Scientific
• 6.59. Exact Sciences
• 6.60. Fabric Genomics
• 6.61. Fluxion Biosciences (Cell Microsystems)
• 6.62. Freenome
• 6.63. FUJIFILM Wako Diagnostics
• 6.64. Fujirebio
• 6.65. Fulgent Genetics
• 6.66. Fyr Diagnostics
• 6.67. GeneDx Holdings
• 6.68. GeneFirst Ltd.
• 6.69. Genetron Holdings
• 6.70. GenomOncology
• 6.71. GILUPI Nanomedizin
• 6.72. Guardant Health
• 6.73. HansaBiomed
• 6.74. HTG Molecular Diagnostics
• 6.75. iCellate
• 6.76. ICON PLC
• 6.77. Illumina
• 6.78. Incell Dx
• 6.79. Inivata
• 6.80. INOVIQ
• 6.81. Invitae Corporation
• 6.82. Invivogen
• 6.83. Invivoscribe
• 6.84. J&J Innovative Medicine
• 6.85. Lucence Health
• 6.86. Lunglife AI Inc
• 6.87. MDNA Life SCIENCES, Inc.
• 6.88. MDx Health
• 6.89. Menarini Silicon Biosystems
• 6.90. Mesa Laboratories, Inc.
• 6.91. Metabiomics Corp
• 6.92. Millipore Sigma
• 6.93. Miltenyi Biotec
• 6.94. miR Scientific
• 6.95. Myriad Genetics
• 6.96. Nanostring
• 6.97. NantHealth, Inc.
• 6.98. Natera
• 6.99. NeoGenomics
• 6.100. NGeneBio
• 6.101. Novogene
• 6.102. Oncimmune
• 6.103. Oncocyte
• 6.104. OncoDNA
• 6.105. Oncohost
• 6.106. OraLiva
• 6.107. Oxford Nanopore Technologies
• 6.108. PamGene
• 6.109. Panagene
• 6.110. Personalis
• 6.111. Perthera
• 6.112. PGDx (Labcorp)
• 6.113. Precipio
• 6.114. PrecisionMed
• 6.115. Predicine
• 6.116. Predictive Oncology
• 6.117. Prenetics
• 6.118. Promega
• 6.119. Qiagen
• 6.120. QuidelOrtho
• 6.121. Rarecells SAS
• 6.122. RareCyte
• 6.123. Revvity
• 6.124. Roche Diagnostics
• 6.125. Screencell
• 6.126. Sherlock Biosciences
• 6.127. Siemens Healthineers
• 6.128. simfo GmbH
• 6.129. Singlera Genomics Inc.
• 6.130. Singular Genomics
• 6.131. Singulomics
• 6.132. SkylineDx
• 6.133. Standard BioTools
• 6.134. Stilla Technologies
• 6.135. Sysmex Inostics
• 6.136. Tempus Labs, Inc.
• 6.137. Thermo Fisher Scientific
• 6.138. Todos Medical
• 6.139. Ultima Genomics
• 6.140. Variantyx
• 6.141. Vela Diagnostics
• 6.142. Veracyte
• 6.143. VolitionRX
• 6.144. Vortex Biosciences
• 6.145. Zhejiang Orient Gene Biotech

7. The Global Market for MDx Cancer

• 7.1. MDx Cancer - Global Market Overview by Country
  • 7.1.1. Table - Global Market by Country
  • 7.1.2. Chart - Global Market by Country
• 7.2. Global Market by Cancer Type - Overview
  • 7.2.1. Table - Global Market by Cancer Type
  • 7.2.2. Chart - Global Market by Cancer Type - Base/Final Comparison
  • 7.2.3. Chart - Global Market by Cancer Type - Base Year
  • 7.2.4. Chart - Global Market by Cancer Type -Final Year
  • 7.2.5. Chart - Global Market by Cancer Type - Share by Year
  • 7.2.6. Chart - Global Market by Cancer Type - Segment Growth
• 7.3. Global Market by Product Type - Overview
  • 7.3.1. Table - Global Market by Product Type
  • 7.3.2. Chart - Global Market by Product Type - Base/Final Comparison
  • 7.3.3. Chart - Global Market by Product Type - Base Year
  • 7.3.4. Chart - Global Market by Product Type -Final Year
  • 7.3.5. Chart - Global Market by Product Type - Share by Year
  • 7.3.6. Chart - Global Market by Product Type - Segment Growth
• 7.4. Global Market by Place - Overview
  • 7.4.1. Table - Global Market by Place
  • 7.4.2. Chart - Global Market by Place - Base/Final Comparison
  • 7.4.3. Chart - Global Market by Place - Base Year
  • 7.4.4. Chart - Global Market by Place -Final Year
  • 7.4.5. Chart - Global Market by Place - Share by Year
  • 7.4.6. Chart - Global Market by Place - Segment Growth

8. Global Market by Cancer Type

• 8.1. MDx Breast Cancer
  • 8.1.1. Table Breast Cancer Testing - by Country
  • 8.1.2. Chart - Breast Cancer Testing Growth
• 8.2. MDx Colorectal Cancer
  • 8.2.1. Table Colorectal Cancer Testing - by Country
  • 8.2.2. Chart - Colorectal Cancer Testing Growth
• 8.3. MDx Cervical Cancer
  • 8.3.1. Table Cervical Cancer Testing - by Country
  • 8.3.2. Chart - Cervical Cancer Testing Growth
• 8.4. MDx Lung Cancer
  • 8.4.1. Table Lung Cancer Testing - by Country
  • 8.4.2. Chart - Lung Cancer Testing Growth
• 8.5. MDx Prostate
  • 8.5.1. Table Prostate Testing - by Country
  • 8.5.2. Chart - Prostate Testing Growth
• 8.6. MDx Melanoma Cancer
  • 8.6.1. Table Melanoma Cancer Testing - by Country
  • 8.6.2. Chart - Melanoma Cancer Testing Growth
• 8.7. MDx Blood
  • 8.7.1. Table Blood Testing - by Country
  • 8.7.2. Chart - Blood Testing Growth
• 8.8. MDx Companion Dx Development
  • 8.8.1. Table Companion Dx Development - by Country
  • 8.8.2. Chart - Companion Dx Development Growth
• 8.9. MDx Other Cancer
  • 8.9.1. Table Other Cancer Testing - by Country
  • 8.9.2. Chart - Other Cancer Testing Growth

9. Global Market by Product Type

• 9.1. MDx Instruments
  • 9.1.1. Table Instruments - by Country
  • 9.1.2. Chart - Instruments Growth
• 9.2. MDx Reagents
  • 9.2.1. Table Reagents - by Country
  • 9.2.2. Chart - Reagents Growth
• 9.3. MDx Software and Services
  • 9.3.1. Table Software and Services - by Country
  • 9.3.2. Chart - Software and Services Growth

10. Global Market by Place

• 10.1. MDx Clinical Laboratory
  • 10.1.1. Table Clinical Laboratory - by Country
  • 10.1.2. Chart - Clinical Laboratory Growth
• 10.2. MDx Pharmaceutical
  • 10.2.1. Table Pharmaceutical - by Country
  • 10.2.2. Chart - Pharmaceutical Growth
• 10.3. MDx Research
  • 10.3.1. Table Research - by Country
  • 10.3.2. Chart - Research Growth

11. Cancer Treatment and Trials

• 11.1. FDA Approvals by Year and Application
• 11.2. Clinical Trials Starts
• 11.3. Prevalence of Cancer Treatments

12. Appendices

• 12.1. United States Medicare System: Clinical Laboratory Fees Schedule
• 12.2. The Most Used IVD Assays
• 12.3. The Highest Grossing Assays
• 12.4. FDA Approved Human Genetic Tests
• 12.5. FDA Approved Pharmacogenomics Tests

관련자료